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Infectious diseases are still the leading cause of death in the world.  The accurate 
technique for early detection and determination of the exact location of infection in 
the body is still needed. Nuclear techniques are capable for this purpose while other 
techniques such as MRI, USG and CT-SCAN sometimes cannot be applied. 99mTc-
kanamycin radiopharmaceutical is complex of kanamycin and technetium-99m 
radionuclide, was used for bacterial detection of infection. The labeling studies of 
99mTc-kanamycin has been carried out by the indirect labeling method using 
pyrophosphate as a co-ligand with the results of labeling efficiency above 95%. 
However, the presence of radiochemical impurities in the form of 99mTc-
pyrophosphate in the indirect labeling have to be considered which may interfere 
the imaging result. This study aimed to determine the optimum labeling conditions 
of 99mTc-kanamycin by direct labeling method. Kanamycin was successfully labeled 
with technetium-99m through direct labeling method. The labeling efficiency was 
determined by ascending paper chromatography using Whatman 3 paper  as the 
stationary phase, and acetone as the mobile phase to separate the radiochemical 
impurities in the form of 99mTc-pertechnetate. While impurities in the form of 99mTc-
reduced  were separated using the stationary phase ITLC-SG and 0.5 N NaOH as 
mobile phase. The experiment result showed that the optimum labeling conditions 
obtained by using 5 mg kanamycin, 30 µg SnCl2.2H2O, and pH of labeling was 9. 
The incubation time of labeling was 30 min at room temperature, provided labeling 
efficiency of 92.31 ± 1.74 %. The successful of kanamycin labeling with high 
efficiency makes 99mTc-kanamycin can potentially be used as a radiopharmaceutical 
for the early detection of infectious diseases. 
 
© 2015 Atom Indonesia. All rights reserved 
 
INTRODUCTION 
 
Infection is the invasion and proliferation of 
microorganisms in body tissue. Clinically, an 
infection may not be apparent; however, local 
cellular injury may arise instead as a result of 
metabolism competition, toxins, intracellular 
replication, or antigen-antibody response [1]. 
Infectious diseases are one of the global health 
problems both in developed countries and in 
developing countries such as Indonesia. One disease 
which is caused by infections, or infectious disease, 
namely the tuberculosis (TB), still puts a strain on 
public health, being second only to HIV/AIDS in 
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causing high mortality rates [2]. It has been reported 
that in 2013, there were about 9 million new cases 
and 1.5 million deaths due to TB [2-4] with about 
two billion people latently infected [5]. Over 95%  
of TB deaths occur in low- and middle-income 
countries, and it is among the top three causes of 
death for women aged 15 to 44 [2]. Those TB deaths 
occur because of late identifications of main 
infections which occur in very deep parts of the 
body (deep-seated infection). The preferential 
detection of infection from sterile inflammations is 
one of the most difficult problems in medicine [6]. 
The available imaging techniques such as                    
Plain Radiography, Ultrasonography, Magnetic 
Resonance Imaging (MRI) and Computed 
Tomography (CT) have high sensitivity but are not 
specific for infection especially in early phases, 
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when anatomical structures have not been distorted 
[6]. Early detection and determination of the exact 
and accurate location of the infection are 
indispensable. Here, nuclear techniques could 
complement the shortcomings of the other 
techniques.  
The latest research activities in the field use 
68
Ga-labeled radiopharmaceuticals with 
68
Ga or 
18
FDG and utilize PET/CT facilities for detecting 
infection [7-12]. A novel approach using 
radioactive-labelled antibiotics or antimicrobial 
peptides labelled with radionuclides, or radiolabeled 
antibiotics or antimicrobial peptides, could be a 
solution to distinguishing between infective                   
and non-infective inflammations [1,3,14-21]. 
Researchers at PSTNT-BATAN have successfully 
developed two kinds of radiolabeled antibiotic, 
namely 
99m
Tc-ciprofloxacin [22] and 
99m
Tc-
ethambutol [23]. The use of infecton (
99m
Tc-
ciprofloxacin) is a sensitive technique that aids in 
the earlier detection and treatment of a wide variety 
of deep-seated bacterial infections. The ability to 
localize infective foci accurately is also important 
for surgical intervention, such as drainage of 
abscesses. In addition, serial imaging with infecton 
is probably useful in monitoring clinical response 
and optimizing the duration of antimicrobials [24]. 
99m
Tc-ethambutol is a specific and sensitive 
radiopharmaceutical to detect and determine the 
location of mycobacterial TB at an early stage in the 
anatomy of the body. The mycobacterial lesion 
uptake study in humans suggested that 
99m
Tc-
etambutol is specific and sensitive 
radiopharmaceutical for resistant tubercular lesion 
detection and localization [25]. 
The Staphylococcus aureus (S. aureus) is one 
the microorganisms most frequently involved in the 
pathogenesis of infection in clinical practice [6]. 
Kanamycin (Fig. 1) is an antibiotic belonging to the 
aminoglycosides that act by binding to the bacterial 
ribosome, thereby inhibiting protein synthesis and 
generating errors in the translation of the genetic 
code [26]. Its nature as a broad-spectrum antibiotic 
allows it to bind to Gram-negative and Gram-
positive bacteria. It was first discovered in Japan in 
1957 by Umezawa et al., is obtained from the 
culture filtrate of Streptomyces kanamyceticus.  
Kanamycin is used to treat infections when 
penicillin or other less toxic drugs cannot be used. 
Infections treated include: bone-, respiratory-tract-, 
skin-, soft-tissue-, and abdominal infections, 
complicated urinary-tract infections; endocarditis; 
septicemia; and enterococcal infections [27].            
Based on the structure-activity relationships study 
of the aminoglycoside antibiotics conducted by 
Benveniste and Davies or S. Salian et al., the 
activity of this class of antibiotics is related to the 
position of hydroxyl groups and amines as 
substituents on R and R' (Fig 1). Kanamycin B and 
C are derivatives of kanamycin A. From in-vitro 
inhibition test of the antibiotic kanamycin of phage 
R17 RNA, it was found that kanamycin B has a 
stronger activity than kanamycin A, while 
kanamycin C has the weakest activity compared to 
both kanamycin A and B [28-29]. More researches 
have been devoted to chemical modification of 
aminoglycoside antibiotics such as kanamycin with 
the goal of increasing antibacterial activities or new 
activities as antibacterial [30-33]. 
 
 
 
Fig. 1. Chemical structure of kanamycin. 
 
99m
Tc-kanamycin labeling studies have been 
carried out in the previous research by the indirect 
method using pyrophosphate as a co-ligand with the 
result of labeling efficiency of above 95% [34-36]. 
However, the presence of radiochemical impurities 
in the form of 
99m
Tc-pyrophosphate in this indirect 
labelling method may interfere with the imaging 
results. The accumulation of 
99m
Tc-pyrophosphate 
in the bone made it difficult to distinguish between 
an infection of the bone and the uptake of 
99m
Tc-
pyrophosphate. Therefore, this study was conducted 
to label the antibiotic kanamycin with radionuclide 
99m
Tc by the direct method. In addition, as the 
strong and broad-spectrum antibiotic kanamycin is 
expected to be able to detect the presence of 
infection in the human body, so 
99m
Tc-kanamycin 
can be used as a radiopharmaceutical for detecting 
infections.  
 
 
 
EXPERIMENTAL METHODS 
 
The materials used to carry out this research 
were kanamycin sulfate (Meiji), tin(II) 
chloride/SnCl2 (Sigma-Aldrich), acetone (E. 
Merck), sodium hydroxide (E. Merck), 
physiological sodium chloride (IPHA), sterile 
aquabidest (double-distilled water) (IPHA), pH 
indicator (E. Merck), Whatman no. 3 paper 
chromatography, and ITLC-SG (Agilent). 
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The equipment used in this experiment 
consists of dose calibrator (Victoreen), vortex 
mixer, single channel analyzer (Ortec), and paper 
chromatography apparatus. 
 
 
Labeling kanamycin with direct method 
 
The direct labeling of kanamycin with 
99m
Tc 
was performed using SnCl2.2H2O as reducing agent. 
The optimum conditions were obtained by varying 
the various parameters such as amount of reducing 
agents, amount of kanamycin, pH level, and 
incubation time. The labeling process was carried 
out by adding a solution of SnCl2 (1 mg/mL in 
water) into a solution of kanamycin in water; the pH 
of the solution was adjusted by adding 0.1 N NaOH 
/ HCl. Then, a saline solution of 
99m
TcO4
– 
with an 
activity of 2-5 mCi was injected into the vial and its 
volume was adjusted to 2 mL. All experiments were 
carried out in a volume of 2 mL and with incubation 
at room temperature. 
 
 
Determination of labeling efficiency of 
99mTc-kanamycin 
 
The determination of labeling efficiency was 
done simultaneously with the determination of the 
radiochemical purity of 
99m
Tc-kanamycin using 
ascending paper chromatography method  using 
Whatman no. 3 paper (10 × 1 cm) as the stationary 
phase and acetone as the mobile phase to separate 
the impurities of 
99m
Tc-pertechnetat (
99m
TcO4
-
) form 
at Rf = 1.0. Meanwhile, to separate the impurity of 
99m
Tc-reduced (
99m
TcO2), ITLC-SG (10 × 1 cm) was 
used as the stationary phase and 0.5 N NaOH as a 
mobile phase where Rf of 
99m
TcO2 = 0.0.                     
The chromatograms were dried in oven at 80 
o
C for 
five minutes, and then every 1 cm piece of paper 
was cut and measured using single-channel gamma 
counter with detector NaI(Tl). 
 
 
Optimization of reducing agent SnCl2.2H2O 
amount 
 
The determination of the optimal amount of 
reducing agent was performed as follows: To a 
series of vials containing kanamycin solution (6 
mg/mL), solutions of SnCl2 (1 mg/mL) of varying 
amounts (20, 35, 30, and 35 μL) were added. The 
pH of the mixture was adjusted to 6-7 by adding a 
0.5 N NaOH solution, and then a solution 
Na
99m
TcO4 with an activity of 2-5 mCi was added. 
The final volume was then adjusted to 2 mL. The 
mixture was shaken with a vortex mixer until 
homogenous and was then incubated at room 
temperature for 30 minutes. The optimum amount 
of reducing agent was determined from the labeling 
efficiency of 
99m
Tc kanamycin using paper 
chromatographic method as described above. 
 
 
Optimization of kanamycin amount 
 
Into each vial containing varying 
concentrations of kanamycin (3, 4, 5, 6, and                 
7 mg/mL) was added 30 µL solution of SnCl2              
(1 mg/mL). The solution's pH was adjusted to                
6-7 by the addition of 0.5 N NaOH solution. After 
the addition of all reagents, then 2-5 mCi of 
99m
TcO4
–
 in saline was injected into each vial so that 
the final volume in all experiments was 2 mL.               
The mixture was shaken with a vortex mixer and 
incubated at room temperature for 30 minutes.               
The optimum amount of kanamycin was determined 
from the labeling efficiency of 
99m
Tc kanamycin 
using paper chromatographic method. 
 
 
Optimization of pH  
 
Into five vials, each containing 1 mL 
kanamycin (5 mg/mL), 30 µL of SnCl2 solution              
(1 mg/mL) was added. The mixture was shaken 
gently until homogeneous. The pH of the solutions 
in those vials was adjusted to 4, 5, 6, 7, 8 and 9, 
respectively, by adding 0.5 N NaOH, and then to 
the mixture was added a solution of Na
99m
TcO4 with 
activity of 2-5 mCi, and the final volume of the 
mixture was adjusted to 2 mL. The mixtures were 
shaken gently until homogeneous and incubated at 
room temperature for 30 minutes. The optimum pH 
was determined from the labeling efficiency of 
99m
Tc kanamycin using a paper chromatographic 
method. 
 
 
Optimization of incubation time  
 
Labeling was done by adding 30 µL of SnCl2 
solution (1 mg/mL) into a vial containing 5 mg of 
kanamycin that was dissolved in 1 mL of 
aquabidest and stirring gently until homogeneous. 
The mixture was incubated for 15 minutes at room 
temperature and then the pH was adjusted to 9 by 
addition of 0.5 N NaOH. After the intended pH of 
the mixture was reached, then 2-5 mCi of 
Na
99m
TcO4 solution was added and the final volume 
of the solution was adjusted to 2 mL. The mixture 
was stirred gently until homogeneous and incubated 
at room temperature for varying periods of 15, 20, 
25, and 30 minutes. The optimum incubation time is 
133 
E.M. Widyasari  et al. / Atom Indonesia Vol. 41  No. 3  (2015)  131 - 137 
 
 
the time that gives a high labeling efficiency of 
99m
Tc-kanamycin. The labeling efficiency was 
determined when the intended incubation interval 
was reached; the labeling efficiency was determined 
using a paper chromatography method. 
 
 
 
RESULTS AND DISCUSSION 
 
A radiopharmaceutical could be defined as a 
chemical substance that contains one or more 
radioactive atoms within its structure and is suitable 
for administration to humans for diagnosis                      
or treatment of a disease [37]. The 
99m
Tc-
radiopharmaceuticals which are used for clinical 
purpose in nuclear medicine have been developed 
from the mid-1960s until now. 
99m
Tc-
radiopharmaceuticals are metal complexes, 
prepared by reducing 
99m
Tc-pertechnetate to a lower 
oxidation state. The coordination complexes of 
technetium are formed of bonds between 
technetium acting as Lewis acid, and atoms or 
functional groups, which act as Lewis bases [38]. In 
preparing a new radiopharmaceuticals, there are 
several factor to be considered, one of them is the 
compatibility of the isotope will be incorporated 
into the molecule to be labeled [39]. Kanamycin 
has several functional groups such as –NH2, –OH, 
and –O– to form bonds with 99mTc. Although the 
details of the chemistry of formation and molecular 
structure are unknown, 
99m
Tc-Kanamycin is 
assumed to be a chelate complex with one or more 
Kanamycin ligands attached to reduced 
99m
Tc [27]. 
Using chemical software (Chem Bio Ultra 11.0) by 
considering electronegativity of functional groups 
that have electrons donor and steric hindrance, we 
assumed  the chelate complex of 
99m
Tc-kanamycin 
are oxo-technetium complexes that shown in Fig. 2. 
The statement was based on the quite large number 
of radiopharmaceutical which have a +5 oxidation 
state with TcO
3+ 
or TcO2
+
 core. So, the possible core 
complexes of 
99m
Tc-kanamycin are TcO(N)4 or 
TcO2(N)4 core complexes. Based on Technetium 
Chemistry and Radiopharmaceutical Applications 
book [40], the reaction of technetium with 
compounds in alkaline solution will produce the 
oxo-technetium complexes (TcO(N)4), whereas 
dioxo-technetium complex (TcO2(N)4) is usually 
obtained from reaction with compounds in organics 
solutions such as THF. There are two possible 
geometric structures for TcO
3+
, square pyramidal or 
octahedral. Figure 2 shows that 
99m
Tc-kanamycin 
complexes have five coordinate groups with an oxo 
group at the apex and four nitrogen atoms at the 
corners so the possible geometric structure for 
99m
Tc-kanamycin is square pyramidal. 
 
 
 
 
Fig 2. Complex of 99mTc-kanamycin. 
 
In general, metal salts such as stannous 
chloride are not soluble in aqueous solution unless 
the pH is quite low. Stannous chloride acts as 
reducing agent when dissolved in hydrochloric acid, 
in which a hexacoordinate tin-chloro coordination 
complex is formed; the complex keeps the tin 
soluble (Reaction 1). 
 
      SnCl2 + 4 Cl
-
              [ SnCl6]
4
         (1) 
 
When the pH is raised to between 1.2 and 
4.5, the insoluble hydrolysis product tetratin(II) 
hexahydroxide dichloride, Sn4(OH)6Cl2, is formed. 
At pH higher than 5.5, an amorphous hydrous 
oxide, Sn5O3(OH)4, is formed. The formation of 
these insoluble hydroxide complexes can be 
prevented by addition of chelating agents to 
sequester the stannous ion as a metal chelate [41]. 
The direct labeling in this study did not use a 
chelating agent for preventing the formation of the 
insoluble Sn-hydroxide. Stannous chloride was 
reacted with kanamycin for a duration before 
adjusting pH. Moreover, in this experiment 
stannous chloride was dissolved in hydrochloric 
acid (5 mg SnCl2 in 0.5 ml 1 N HCl and 4.5 ml 0.1 
N HCl) to create an acidic condition. In acidic 
conditions, the amine and the hydroxyl in 
kanamycin structure would be converted to 
protonated form (Reaction 2 and 3). The protonated 
form of kanamycin would be more positively 
charged; therefore, it would be easy to bind with 
[SnCl6]
4-
. The formation of those chelates will avoid 
the solution from becoming turbid when the pH               
is increased. 
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(2) 
                    
 
 
 
 
 
(3) 
             
 
 
 
In this preparation, the values of the 
parameters which influence of the labeling process 
were varied. Some of those parameters are the 
amount of reducing agent (SnCl2), the amount of 
ligand (kanamycin), pH, and incubation time. In 
this research, a reducing agent for labeling process 
plays an important role because no effective 
chemical technique is available to attach a 
pertechnetate ion to an organic moiety. The 
reduction of 
99m
TcO4
-
 (Tc(VII)) to a lower oxidation 
state is a prerequisite for 
99m
Tc-complex formation 
in high yield and purity [38]. This experiment's 
result showed that the amount of the reducing agent, 
SnCl2.2H2O, which gave the highest labeling 
efficiency was 30–35 μg. Consequently, a value of 
30 μg of SnCl2.2H2O was chosen (Fig. 3); it is an 
optimum value of the reducing agent with the 
highest labeling efficiency. This suggests that 
amounts of reducing agents of less than 30 µg                
were not enough to reduce 
99m
TcO4
-
 to a lower 
oxidation state. 
The optimal amount of ligand in the labeling 
process of 
99m
Tc-kanamycin is shown in Fig. 4. The 
highest efficiency was 91.09 ± 0.90 %, attained 
with 5 mg of kanamycin. This result is the same as 
the optimum ligand in Roohi's experiment [27]. 
Radiochemical impurities in this labeling are 
99m
TcO4
-
 (free pertechnetate) and 
99m
TcO2 (
99m
Tc-
reduce). The amount of radiochemical impurities 
present has to be minimized, as a poor 
radiophamaceutical quality will affect the clinical 
information. According to the radiochemical purity 
(RCP) requirement from The United States 
Pharmacopeia, there are different RCP limit values 
of the radiopharmaceuticals based on USP 
monographs, package inserts, and published 
literature. The minimum RCP limits listed in the 
USP 27 were >80% [41]. Impurities in the form of 
99m
TcO4
-
 will interfere with the imaging of the 
thyroid region, while 
99m
TcO2 will interfere with the 
imaging of the liver. 
 
 
Fig 3. Effect of SnCl2.2H2O amount on the labeling efficiency 
of 99mTc-Kanamycin. 
 
 
 
Fig 4. Effect of kanamycin amount on the labeling efficiency of 
99mTc-Kanamycin. 
 
The labeling efficiency of 
99m
Tc-kanamycin 
decreases for the use of less than 5 mg of 
kanamycin (Fig. 4). This result indicates that 
amounts of the ligand of less than 5 mg was not 
enough to react with reduced 
99m
Tc to produce 
99m
Tc-kanamycin complex. Additionally, from t-test 
with a confidence level of 95%, for amounts of the 
ligand of more than 5 mg, the percentages of 
labeling efficiency were not significantly different 
with that of 5 mg of the ligand. 
As described above, the reaction between 
SnCl2 and kanamycin took place under acidic 
condition with pH of about 3. Incubation times 
between SnCl2 and kanamycin are presented in Fig. 
5. It appears that labeling efficiencies of more than 
90% occurred for 10-30 minutes of reaction time 
and 15 minutes of incubation time, respectively. 
The incubation time was chosen to be 15 minutes 
since the labeling efficiency for an incubation time 
of about 15 minutes exceeded 90% (safe zone). 
Choosing an incubation time of 30 minutes results 
in the highest labeling efficiency, but it requires 
care because the labeling efficiency will decrease 
for incubation times of more than 30 minutes. This 
decrease is due to the reduction reaction kanamycin 
by SnCl2. This reaction would decrease SnCl2 
reactivity for reducing pertechnetates, as shown by 
the increasing impurities in the form of 
99m
TcO4
-
. 
Alcohol Strong acid 
Protonated 
alcohol 
Amine Strong acid 
Protonated  
amine 
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Fig 5. Effect of  incubation time before adjust pH. 
 
The effect of pH on the 
99m
Tc-kanamycin 
labeling process is shown in Fig. 6. The labelling 
efficiency increased in alkaline conditions and the 
highest labeling efficiency was obtained at pH = 9. 
This optimum condition is suitable for the chemical 
characteristic of kanamycin, as in alkaline 
conditions amine or hydroxyl groups would be in 
deprotonated form. Deprotonated amine and 
hydroxyl groups have more electrons to be donated 
than their normal forms, so they will more easily 
form complexes with 
99m
Tc to produce 
99m
Tc-
kanamycin. As reported by Roohi et al. [27], the 
complexation of 
99m
Tc with kanamycin is not rapid 
and the maximum labeling efficiency is achieved 
after 30 minutes at room temperature (Fig. 7). 
 
 
 
Fig 6. Effect of pH on the labeling efficiency of 99mTc- 
Kanamycin. 
 
 
Fig 7. Effect of incubation time on the labeling of 99mTc-
Kanamycin. 
CONCLUSION 
 
Kanamycin was successfully labeled with 
99m
Tc by direct methods, which resulted in a 
99m
Tc-
kanamycin labeling efficiency of 92.31 ± 1.74%. 
The optimum conditions obtained from this 
investigation consist of 30 µg SnCl2.2H2O as 
reducing agent, 5 mg kanamycin as a ligand,                    
a pH of 9, and incubation at room temperature for 
30 minutes. The preparation is preceded first by 
reacting stannous chloride with kanamycin for 
several minutes before adjusting the pH for the 
labeling process to prevent the formation of 
insoluble hydroxide complexes of stannous chloride 
in the alkaline solution. 
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